Weekly Ards Research Analysis
This week’s ARDS literature highlights mechanistic advances linking innate immunometabolism to NETosis control, high-fidelity epithelial multi-omics of viral injury, and improved prognostic enrichment in pediatric ARDS. A D1-like dopamine–macrophage–NETosis axis emerges as a translational target; paired single-nucleus RNA/ATAC organoids define conserved AT2 injury and bystander programs during influenza; and CCL7/IL-18–based cytokine models improve risk stratification in children. Together these
Summary
This week’s ARDS literature highlights mechanistic advances linking innate immunometabolism to NETosis control, high-fidelity epithelial multi-omics of viral injury, and improved prognostic enrichment in pediatric ARDS. A D1-like dopamine–macrophage–NETosis axis emerges as a translational target; paired single-nucleus RNA/ATAC organoids define conserved AT2 injury and bystander programs during influenza; and CCL7/IL-18–based cytokine models improve risk stratification in children. Together these studies accelerate targeted biologic interventions, phenotype-guided care, and biomarker-driven trial design.
Selected Articles
1. Dopamine signaling reprograms macrophage FAO to alleviate acute lung injury by inhibiting NETosis via the CXCL10-CXCR3 axis.
This mechanistic study shows accelerated dopamine turnover in ALI and that D1-like receptor signaling enhances macrophage CPT1A-dependent fatty acid oxidation and mitochondrial fitness, suppressing MAPK/NF-κB and NLRP3 and limiting NETosis via IL-10–mediated inhibition of the CXCL10–CXCR3 axis. Findings were conserved in human macrophages, positioning dopaminergic modulation as a translational target.
Impact: Uncovers a conserved cross-cell mechanism linking neurotransmitter signaling to macrophage immunometabolism and neutrophil NETosis control, offering a tractable therapeutic axis in ALI/ARDS.
Clinical Implications: Supports exploration of D1-like receptor agonists or metabolic modulation (CPT1A/FAO enhancement) to rebalance innate immunity and reduce NETosis-driven lung injury; requires preclinical safety/dose work and early-phase trials before clinical use.
Key Findings
- ALI associated with accelerated dopamine turnover in the lung inflammatory milieu
- D1-like receptor signaling enhances CPT1A-dependent FAO and mitochondrial fitness in macrophages
- Macrophage-derived IL-10 inhibits the CXCL10–CXCR3 axis, restraining neutrophil hyperactivation and NETosis
- Protective mechanism conserved in human macrophages from donors and ARDS patients
2. Early cell-autonomous and niche-mediated epithelial response to influenza infection in primary alveolar organoids.
Using murine and human primary alveolar organoids with paired single-nucleus RNA/ATAC multi-omics, the study establishes robust IAV infection models and delineates a conserved AT2 injury program: early surfactant loss, decreased lipid biogenesis, rapid antiviral burst, and late suppression. Uninfected AT2 cells rapidly adopt damage-associated states via inflammatory niche signals, highlighting bystander mechanisms relevant to ARDS pathogenesis.
Impact: Provides a high-resolution, cross-species map of early alveolar epithelial responses and bystander injury mechanisms, creating candidate molecular signatures and targets for early intervention in viral ARDS.
Clinical Implications: Suggests candidate early biomarkers (surfactant-related and lipid pathways) and intervention targets to preserve AT2 function; supports validating organoid-derived signatures in patient BAL/autopsy samples for diagnostic and therapeutic trial enrichment.
Key Findings
- Established robust IAV infection in primary murine and human alveolar organoids
- Infected AT2 cells show early surfactant secretion loss and decreased lipid biogenesis followed by antiviral response dynamics
- Uninfected AT2 cells undergo rapid transcriptional and epigenomic reprogramming to damage-associated states driven by the inflammatory niche
3. Cytokine-based strategies to improve prognostic enrichment of pediatric ARDS.
In a prospective multicenter cohort (LEOPARDS, n=500), the adult IL-6/TNFR1/bicarbonate signature had modest prognostic value. Inclusion of CCL7 (and IL-18 ± TNFR1) produced parsimonious models with improved mortality discrimination (training AUROC 0.72–0.73; validation AUROC 0.66) and ~40% net reclassification improvement, suggesting practical cytokine panels for pediatric prognostic enrichment.
Impact: Provides internally validated, parsimonious cytokine models (CCL7/IL-18) that materially improve prognostic enrichment in pediatric ARDS, aiding trial design and targeted interventions for high-risk children.
Clinical Implications: Early measurement of CCL7 and IL-18 could be used to enrich pediatric ARDS cohorts for high-risk status in trials and to prioritize candidates for immunomodulatory strategies; external validation and threshold definition are next steps.
Key Findings
- Adult 3-term hyper-/hypo-inflammatory signature (IL-6, TNFR1, bicarbonate) had modest utility (AUC 0.62)
- CCL7 was the cytokine most strongly associated with 90-day mortality (p < 0.0001)
- Parsimonious models with CCL7 and IL-18 improved training AUROC to 0.72–0.73 and validation AUROC to 0.66 with ~40% net reclassification gain